Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Coronary Artery Disease
Interventions: Dabigatran, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Scar Formation
Interventions: GBT009, Placebo; Biological
Lead sponsor: Garnet BioTherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, New York

Conditions: Chronic Heart Failure With Reduced Systolic Function
Interventions: Dapagliflozin, Dapagliflozin matching placebo; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 25
States / cities: Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more

Conditions: Premenstrual Syndrome
Interventions: Fluoxetine, Calcium, Placebo; Drug
Lead sponsor: Donaghue Medical Research Foundation; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions: Elinzanetant (BAY3427080), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 55
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more

Conditions: Perennial Allergic Rhinitis
Interventions: Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%, Placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 39
States / cities: Costa Mesa, California • Long Beach, California • Mission Viejo, California + 34 more

Conditions: Traumatic Brain Injury
Interventions: Placebo, citicoline; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 1,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • Baltimore, Maryland • Philadelphia, Pennsylvania + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Diego, La Jolla, California • Gainesville, Florida

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions: ALK-001, Placebo; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: HIV Infections, Metabolic Syndrome X
Interventions: Metformin, Placebo, Lifestyle Modification; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: ETI-204, "Anthim", placebo; Drug · Other
Lead sponsor: Elusys Therapeutics; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Depressive Disorder
Interventions: memantine, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: HIV-1 Infection
Interventions: Pitavastatin, Placebos; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 75 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Polycystic Ovary Syndrome
Interventions: pioglitazone, metformin, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer, Cardiovascular Disease
Interventions: vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Asthma in-school class, Asthma Day Camp, Health Promotion in-school class; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Years to 13 Years
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Alcohol Dependence
Interventions: citalopram; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Silodosin, Placebo; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 42
States / cities: Birmingham, Alabama • Carmichael, California • Fresno, California + 39 more

Conditions: Lyme Disease
Interventions: VLA15, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 82
States / cities: Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more

Search by objective public record fields.

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Lifestyle Modification and Metformin Use in the Treatment of HIV

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

Memantine Augmentation of Antidepressants

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

Vitamin D and Omega-3 Trial (VITAL)

Asthma in Central Texas Project

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)